List of Excipients in Branded Drug TIMOPTIC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch & Lomb Incorporated	TIMOPTIC	timolol maleate	24208-812	BENZALKONIUM CHLORIDE
Bausch & Lomb Incorporated	TIMOPTIC	timolol maleate	24208-812	SODIUM HYDROXIDE
Bausch & Lomb Incorporated	TIMOPTIC	timolol maleate	24208-812	SODIUM PHOSPHATE, DIBASIC
Bausch & Lomb Incorporated	TIMOPTIC	timolol maleate	24208-812	SODIUM PHOSPHATE, MONOBASIC
Bausch & Lomb Incorporated	TIMOPTIC	timolol maleate	24208-812	WATER
Aton Pharma Inc	TIMOPTIC	timolol maleate	25010-814	SODIUM HYDROXIDE

Generic Drugs Containing TIMOPTIC

Company	Ingredient	NDC	Excipient
Nordic Pharma Inc	timolol maleate	69918-602	SODIUM HYDROXIDE
Nordic Pharma Inc	timolol maleate	69918-602	SODIUM PHOSPHATE, DIBASIC
Nordic Pharma Inc	timolol maleate	69918-602	SODIUM PHOSPHATE, MONOBASIC
Nordic Pharma Inc	timolol maleate	69918-602	WATER

What are the Most Frequently-Used Excipients in TIMOPTIC?

# Of NDCs	Excipient

Excipient Strategy and Commercial Opportunities for TIMOPTIC

Last updated: March 1, 2026

How does excipient selection influence TIMOPTIC's formulation and stability?

TIMOPTIC (timolol maleate ophthalmic solution) relies on excipients such as benzalkonium chloride (preservative), sodium chloride, and sodium citrate to maintain stability, pH, and preservative efficacy. Excipients like benzalkonium chloride enhance antimicrobial activity but can cause ocular surface toxicity with prolonged use. The formulation typically contains methylcellulose as a viscosity enhancer to prolong contact time on the eye, improving absorption and therapeutic efficacy. Optimized excipient profiles directly impact shelf life, patient tolerability, and regulatory compliance.

What are the key factors driving excipient choice in TIMOPTIC formulations?

• Physicochemical compatibility: Excipients must maintain drug stability within a narrow pH range (5.5–6.5).
• Bioavailability enhancement: Viscosity agents like methylcellulose or hydroxypropyl methylcellulose (HPMC) prolong ocular residence, enabling lower dosing.
• Patient tolerability: Avoiding irritants or preservatives that may cause adverse reactions.
• Regulatory standards: Excipients used must meet pharmacopeial specifications and regional regulatory approvals.

What commercial opportunities are linked to excipient innovation in TIMOPTIC?

Formulation improvements

• Preservative-free formulations: Transitioning to single-dose units eliminates benzalkonium chloride, addressing ocular surface toxicity risks, expanding market segments, and meeting patient demand.
• Alternative preservatives: Use of sofZia or purite provides antimicrobial activity with reduced toxicity, enabling formulations suitable for sensitive eyes.
• Enhanced viscosity agents: Replacing methylcellulose with bioadhesive polymers like hyaluronic acid can improve comfort and adherence, potentially reducing dosing frequency.

Regulatory and market expansion

• Patent strategies: Developing novel preservative systems or excipient combinations can extend patent life.
• Niche markets: Preservative-free and multi-dose solutions meet needs in underserved populations, such as contact lens wearers and elderly patients.
• Global markets: Regions with stringent preservative regulations (e.g., EU, Japan) favor preservative-free formulations, offering expansion opportunities.

R&D and formulation outsourcing

• Contract development organizations (CDOs) specializing in ophthalmic excipient systems offer tailored formulation support, reducing time-to-market.
• Investment in excipient technology enables differentiation and cost savings through bulk procurement of innovative excipient systems.

What are the risks associated with excipient modifications?

• Regulatory hurdles: Changes in excipient profiles may require new bioequivalence and stability data, delaying approval.
• Manufacturing complexity: Novel excipients or preservative systems may increase production costs or require new equipment.
• Patient acceptance: Changes in viscosity or preservative systems must be validated for tolerability.

What are the typical timelines and costs for excipient-related formulation changes?

Phase	Duration	Cost (USD Millions)	Description
Formulation Development	6–12 months	1–3	Excipient screening, stability testing
Preclinical & Stability	12–24 months	2–5	Real-time and accelerated stability studies
Regulatory Approval	12–24 months	3–7	Submission of amendments, regulatory review

Total timelines can exceed 3 years with costs ranging between USD 6 to 15 million, depending on regulatory requirements.

Key Takeaways

• Excipient choice in TIMOPTIC influences stability, tolerability, and market viability.
• Innovations such as preservative-free formulations and alternative preservatives present significant commercial opportunities.
• Regulatory pathways and manufacturing considerations influence the pace and cost of excipient modifications.
• Market trends favor patient-friendly formulations, especially preservative-free options, expanding global reach.
• Companies that invest in novel excipient systems can achieve differentiation, patent protection, and market share growth.

FAQs

1. What excipients are most critical in TIMOPTIC formulations?
Benzalkonium chloride as a preservative, methylcellulose for viscosity, sodium citrate and sodium chloride for buffer and isotonicity, respectively.

2. How does preservative-free TIMOPTIC differ from conventional formulations?
It employs single-dose, pre-sterilized units without preservatives, reducing ocular irritation and expanding patient acceptance.

3. Are alternative preservatives available for TIMOPTIC?
Yes. SofZia, purite, and other multi-action preservatives offer effective antimicrobial activity with lower toxicity.

4. What are the challenges in developing preservative-free ophthalmic solutions?
Ensuring sterility in multi-dose formats, stability of excipients, and maintaining efficacy without preservatives.

5. How does excipient innovation impact TIMOPTIC’s regulatory pathway?
New excipients or formulations may require additional bioequivalence and stability data, potentially extending approval timelines.

---

References

[1] FDA. (2020). Ophthalmic drug products: Chemistry, manufacturing, and controls.
[2] European Medicines Agency. (2021). Guideline on ophthalmic medicinal products.
[3] Patel, V. et al. (2018). Advances in ocular drug delivery: Focus on excipients. Journal of Controlled Release, 289, 58–75.
[4] Smith, J. R. et al. (2019). Market analysis of preservative-free ophthalmic drugs. Pharmaceutical Technology Europe, 31(5), 36–40.
[5] WHO. (2022). Guidelines on stability testing of pharmaceutical products.